Advanced

Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study

van Kerrebroevk, Philip; Rezapour, Masoumeh; Cortesse, Ariane; Thueroff, Joachim; Riis, Anders and Norgaard, Jens Peter LU (2007) In European Urology 52(1). p.221-229
Abstract
Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-treated patients compared with seven... (More)
Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-treated patients compared with seven (11%) placebo-treated patients showed a clinical response, defined as a >= 50% reduction in the number of nocturnal voids compared with baseline (p = 0.0014). Compared with placebo, desmopressin resulted in a significant reduction in the mean number of nocturnal voids (39% reduction with desmopressin vs. 15% with placebo; absolute difference -0.84, p < 0.0001) and duration of the first sleep period (prolonged by 108 min with desmopressin vs. 41 min with placebo; p < 0.0001). Quality of sleep was also improved with clesmopressin versus placebo (statistically significant for one of the two parameters evaluated). Adverse events were mainly mild. Conclusions: Oral clesmopressin tablets provide an effective and well-tolerated treatment for nocturia. Compared with placebo, nocturnal voiding frequency is reduced, duration of the first sleep period is increased, and sleep quality may be improved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
nocturia, efficacy, double-blind, antidiuresis, desmopressin, sleep, safety
in
European Urology
volume
52
issue
1
pages
221 - 229
publisher
Elsevier
external identifiers
  • wos:000247281400035
  • scopus:34249062374
ISSN
1873-7560
DOI
10.1016/j.eururo.2007.01.027
language
English
LU publication?
yes
id
6cf523d6-fa76-47a2-b00a-fdd383662546 (old id 648459)
date added to LUP
2007-12-20 12:34:17
date last changed
2017-11-19 04:12:25
@article{6cf523d6-fa76-47a2-b00a-fdd383662546,
  abstract     = {Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged &gt;= 18 yr with nocturia (&gt;= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (&gt;= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to &gt;= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-treated patients compared with seven (11%) placebo-treated patients showed a clinical response, defined as a &gt;= 50% reduction in the number of nocturnal voids compared with baseline (p = 0.0014). Compared with placebo, desmopressin resulted in a significant reduction in the mean number of nocturnal voids (39% reduction with desmopressin vs. 15% with placebo; absolute difference -0.84, p &lt; 0.0001) and duration of the first sleep period (prolonged by 108 min with desmopressin vs. 41 min with placebo; p &lt; 0.0001). Quality of sleep was also improved with clesmopressin versus placebo (statistically significant for one of the two parameters evaluated). Adverse events were mainly mild. Conclusions: Oral clesmopressin tablets provide an effective and well-tolerated treatment for nocturia. Compared with placebo, nocturnal voiding frequency is reduced, duration of the first sleep period is increased, and sleep quality may be improved.},
  author       = {van Kerrebroevk, Philip and Rezapour, Masoumeh and Cortesse, Ariane and Thueroff, Joachim and Riis, Anders and Norgaard, Jens Peter},
  issn         = {1873-7560},
  keyword      = {nocturia,efficacy,double-blind,antidiuresis,desmopressin,sleep,safety},
  language     = {eng},
  number       = {1},
  pages        = {221--229},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study},
  url          = {http://dx.doi.org/10.1016/j.eururo.2007.01.027},
  volume       = {52},
  year         = {2007},
}